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Ciri-ciri Kraniofasial dan Lengkungan Gigi bagi Pesakit 
Talasemia Transfusi- Dependen                                                  
 
ABSTRAK 
 
 
Penyakit talasemia merupakan penyakit yang biasa di Asia Tenggara. Namun maklumat  
berkaitan dengan deformasi kraniofasial dan lengkungan gigi serta kerencatan dalam 
proses pematangan tulang, amatlah terhad.  
 
Tujuan kajian ini adalah untuk menentukan prevalen kecacatan kraniofasial pesakit 
talasemia transfusi dependen (TDT) dan hubungan antara kecacatan ini dengan data 
klinikal. Kajian ini juga adalah untuk membandingkan ukuran sepalometrik, lengkungan 
gigi dan kematangan tulang vertebra servikal di kalangan pesakit talasemia transfusi-
dependen dengan kumpulan biasa kawalan.  
 
Sebahagian dari penyelidikan ini merupakan kajian rentas lintang dimana prevalen 
kecacatan kraniofasial (CFD) di ukur daripada 43 pesakit TDT (purata umur 11.6 ± 4.75 
tahun) dari Hospital Universiti Sains Malaysia (HUSM) menggunakan evaluasi klinikal. 
Data klinikal lain dibandingkan diantara pesakit TDT yang mengalami kecacatan 
kraniofasial (CFD+) dengan mereka yang tanpa kecacatan kraniofasial (CFD-). 
Sebahagian kajian ini pula menggunakan plan perbandingan, kes dan kawalan. Ukuran  
sepalometrik  diukur dengan menggunakan perisian CASSOS 2001. Manakala morfologi 
lengkungan gigi dikaji menggunakan perisian Morpho Studio v3.01. Peringkat 
kematangan vertebra servikal (CVM) di nilai dengan menggunakan kaedah Baccetti et 
al., (2005) dan purata umur setiap peringkat CMV dibandingkan. Ujian Independent t, 
 xvii 
Mann-Whitney test and ujian chi-square dilayari untuk perbandingan hasil kajian. 
Analisis perangkaan telah dilakukan dengan menggunakan perisian Windows SPSS 
12.0.1.  
 
Hasil kajian mendapati prevalen kecacatan kraniofasial ialah 44.2 % dikalangan pesakit 
TDT (95 % CI= 30.2 %, 58.2 %). Tiada perbezaan statistik yang signifikan (P>0.05) 
ditemui antara CFD+ dan CFD- pesakit TDT pada semua data klinikal. Analisia 
sephalometrik menunjukkan perbezaan yang tidak signifikan pada hubungan ukuran 
anteroposterior (P>0.05) tetapi terdapat sedikit peningkatan sudut ANB pada kumpulan 
TDT, manakala, peningkatan ukuran angular mandibel adalah signifikan (P<0.01) pada 
kumpulan pesakit TDT. Kedua kumpulan menunjukkan perbezaan yang tidak signifikan 
(P>0.05) dalam ukuran panjang maksilari manakala ukuran panjang badan mandibel dan 
ramus adalah lebih pendek di kalangan pesakit TDT (P≤0.001). Kedua-dua bibir atas dan 
bawah pesakit TDT menonjol ke depan (P<0.001) dan sudut nasolabialnya lebih kecil 
(P<0.05) berbanding kumpulan kawalan. Analisa lengkungan gigi menggunakan JLinks 
menunjukkan bahawa kumpulan pesakit TDT mempunyai dimensi maksila anterior dan 
mandibel posterior yang lebih kecil sebanyak 3-5%. Akhirnya, pesakit TDT 
menunjukkan (P<0.05) umur kronologikal yang lebih muda berbanding kumpulan 
kawalan pada peringkat servikal 1(CS1) dan kronologikal umur yang sama pada CS2  
sementara mereka lebih tua daripada kumpulan kawalan pada CS3 (P<0.05) dan CS4 
(P>0.05) dan tiada daripada mereka sampai ke CS5 atau CS6. 
   
 xviii 
Kesimpulannya, pesakit TDT mempunyai prevalen yang tinggi dalam kecacatan 
kraniofasial tetapi tiada hubungan kait dengan data klinikal yang di kaji. Mereka 
mempunyai ciri-ciri rahang muka kelas II, penonjolan kedua-dua bibir atas dan bawah ke 
hadapan, pertumbuhan menegak tulang mandibel, lengkungan mandibel dan maksilari 
yang kecil dan kelewatan dalam  kematangan  vertebra servikal.  
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Craniofacial and Dental Arches Characteristics in Transfusion- 
Dependent Thalassaemia Patients 
                                                   
                                                  ABSTRACT   
 
Thalassaemia diseases are common in Southeast Asia. However, information about 
craniofacial and dental arches deformity as well as retardation of skeletal maturation are 
deficient in this area.  
 
The aims of this study were to determine the prevalence of craniofacial deformity (CFD) 
in transfusion-dependent thalassaemia (TDT) patients and the association between this 
deformity and clinical data. It was also to compare cephalometric measurements, dental 
arches features and cervical vertebral maturation of TDT with a normal control group.  
 
This study was a cross sectional study, in part of it; where the craniofacial deformity of 
43 TDT patients (mean age of 11.6 ± 4.75 years) from Hospital Universiti Sains Malaysia 
(HUSM) was evaluated clinically. Clinical data were compared between TDT patients 
with craniofacial deformity (CFD+) and those without it (CFD-). Other parts of this study 
followed a case control design. The cephalometric parameters were measured using 
CASSOS 2001 software. Morpho Studio v3.01 software was used for dental arches 
measurements while the stages of cervical vertebral maturation (CVM) were evaluated 
using Baccetti et al., (2005) method. The mean chronological age of each stage of CVM 
was determined. Independent t test, Mann-Whitney test and chi-square test were utilized 
for previous comparisons. Statistical analyses were done using SPSS 12.0.1 for 
Windows.  
 
 xx 
Prevalence of craniofacial deformity was found to be 44.2% in TDT patients (95% CI= 
30.2 %, 58.2 %). No statistically significant difference (P>0.05) was found between 
CFD+ and CFD- groups in all clinical data. Cephalometric analysis showed no significant 
difference in anteroposterior relationships (P>0.05) but slightly increased ANB angle in 
TDT group while, angular measurements of mandibular position were all significantly 
increased (P<0.01) in TDT group. Both groups showed insignificant difference in 
maxillary length while both mandibular body and ramus lengths were shorter in TDT 
group (P≤0.001). Procumbancy (P<0.001) of upper and lower lips together with smaller 
nasolabial angle (P<0.05) were found in TDT group. Dental arches analyses with JLinks, 
showed that TDT group had narrower maxillary anterior and mandibular posterior 
dimensions by nearly 3-5%. Finally, TDT patients showed younger (P<0.05) 
chronological age in cervical stage 1 (CS1), the same chronological age in CS2 while 
older chronological age in CS3 (P<0.05) and CS4 (P>0.05) compared to control group. 
None of TDT patients has reached CS5 or CS6.  
 
In conclusion, TDT patients had high prevalence of CFD that has no association with 
clinical data studied. TDT patients were characterized by mild class II skeletal pattern, 
protruded upper and lower lips, prominent vertical growth direction of the mandible, 
smaller maxillary and mandibular arches dimensions and retarded cervical vertebral 
maturation. 
 1 
CHAPTER 1 
INTRODUCTION 
 
           Thalassaemia and other haemoglobin disorders are the most common monogenic 
disorders among humans. Nearly 7% of the world's population carriers of potentially 
pathological haemoglobin genes (Weatherall and Clegg, 2001 b, WHO, 2002). Each year 
about 300, 000 infants worldwide are born with haemoglobin disorder; 30% of them with 
thalassaemia (WHO, 2006). β-thalassaemia is most common in the Mediterranean basin, 
Middle East and Asia. Severe alpha thalassaemia is common in Southeast Asia and 
sickle-cell anaemia predominates in Africa (WHO, 2006). Increasing global migration 
has introduced haemoglobin disorders into many areas where they were not originally 
endemic (Vichinsky, 2005).  
 
Haemoglobin E is the most common structural haemoglobin variant globally (Vichinsky, 
2007). It is found in the Eastern half of the Indian subcontinent and throughout Southeast 
Asia where carrier rates may exceed 60% of the population in some areas (Weatherall 
and Clegg, 2001 b). Although HbE trait and HbE disease are asymptomatic conditions, 
the interaction of HbE and β-thalassaemia can cause a severe clinical disorder that 
requires regular transfusion. Indeed, globally HbE/ β-thalassaemia is one of the most 
important varieties of thalassaemia especially in Asia (Weatherall, 2000) (Fig.1.1).  
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Figure 1.1 Distribution of Hb E and β-thalassaemia in Southeast Asia (Source: 
Weatherall and Clegg, 2001 a).  
 
In Malaysia, the most recent data showed 4541 affected thalassaemia patients (Malaysian 
Health Technology Assessment Section, 2009). Nearly 73% of them presented with 
transfusion-dependent β-thalassaemia major and HbE/ β-thalassaemia, 10% with 
thalassaemia intermedia, 9% with HbH disease and the rest with other types of 
thalassaemia. The highest percentage of registered patients was found in East Malaysian 
state of Sabah (28%) while only 3% in Sarawak. In peninsular Malaysia, the distribution 
pattern followed the population density except for predominance of HbE/ β-thalassaemia 
in the Northern states (Malaysian Health Technology Assessment Section, 2009). 
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Management of β-thalassaemia major and some other varieties of thalassaemia requires 
lifelong medical treatment with blood transfusion and iron chelation. Bone marrow 
transplantation is the only chance of a cure, but the availability is limited and the risks are 
considerable (La Nasa et al., 2005). Consequently, these disorders constitute an 
increasing drain on health resources, particularly in those countries that go through 
demographic transition from poverty into stronger economies (WHO, 2002, WHO, 
2005). In such countries, the required treatment for survival of thalassaemia patients is 
becoming available thus, many patients  are now able to reach their second or third 
decade of life (Weatherall, 2005). However, their life course is interrupted with many 
complications.  
 
One of the important aspects of thalassaemia is the skeletal changes affecting cranial and 
facial bones. These changes occur in the form of hypertrophy of the maxilla, protrusion 
of anterior teeth, depression of the bridge of the nose and prominent malar eminences 
producing a characteristic facial feature known as ‘chipmunk face’ or as ‘rodent face’. 
Bossing of the skull, open bite, malocclusion, puffiness of eyelids and a mongoloid slant 
of eyes are other common features of this problem (Duggal et al., 1996, Abu Alhaija et 
al., 2002). Skeletal complications are commonly seen in inadequately treated patients and 
less in patients with optimal treatment (Tyler et al., 2006).  
 
Another frequent aspect of thalassaemia is the retarding effect on the general growth and 
skeletal maturation of the affected patients (De Sanctis et al., 2004, Christoforidis et al., 
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2007). Such complications have negative physical, psychological and social impact on 
thalassaemia patients and their parents (Khurana et al., 2006, Ismail et al., 2006). 
 
It is important to conclude that dealing with the problem of thalassaemia requires efforts 
to develop adequate clinical and laboratory programs for their control. Informations about 
frequency, different forms, severity and complications of the disease must also be defined 
in order to help in providing best diagnostic and therapeutic services for thalassaemia 
patients.  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Historical background 
            The period between 1925 and 1940 saw the first descriptions of the clinical 
features of different form of thalassaemias (Ranney, 2001). The first description of the 
severe form of thalassaemia is accounted to the American paediatrician Thomas B. 
Cooley in 1925, who described four children with anaemia, splenomegaly, enlargement 
of the liver, discoloration of skin and sclera together with a peculiar mongoloid 
appearance caused by enlargement of the cranial and facial bones (Weatherall and Clegg, 
2001 a). Indeed, Cooley was describing the severe life-threatening form of β thalassaemia 
which is still known as Cooley's anaemia. Several Italian clinicians described at about the 
same time, the milder forms of thalassaemia (Bunn and Forget, 1986, Weatherall and 
Clegg, 2001 a). The term ‘thalassaemia’ was first used in 1932 which is derived from a 
Greek word ‘thalassa’ meaning the sea, because all early cases were reported in children 
of Mediterranean origin (Bunn and Forget, 1986). 
 
Theoretical model for the genetic basis of thalassaemia has been established by 1960 
(Ranney, 2001). Afterwards, it was apparent that thalassaemia is not one disease, but a 
very diverse group of genetic disorders, all of which result from abnormal haemoglobin 
synthesis. Furthermore, it became clear that thalassaemia have a widespread distribution 
and not localized to the Mediterranean region. However, a relatively complete 
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understanding of the molecular basis of thalassemia was only available in 1980s (Ranney, 
2001, Weatherall and Clegg 2001 a). 
 
2.2 Thalassaemia in general 
          Thalassaemia is one of the inherited haemoglobin disorders ‘haemoglobinopathies’ 
in which there is inadequate synthesis of globin chain subunits of haemoglobin 
(Weatherall and Clegg, 2001 a). However, the globin chain produced-if any-are generally 
normal in structure (Provan and Gribben, 2000). Haemoglobinopathies include also the 
structural variants of haemoglobin such as haemoglobin S and C that, in contrast with 
thalassaemia, are produced in normal quantities but have altered structure and function. 
In addition, there are variants such as haemoglobin E and Lepore which are both 
quantitavely and qualitatively abnormal (Provan and Gribben, 2000). These variants are 
sometimes called ‘thalassaemia variants’ because they share thalassaemia in the reduced 
rate of globin chain synthesis and hence having the same thalassaemia phenotype  
(Dispenzieri, 2001).   .  
 
Indeed, because these diseases are all so common and occur together in particular 
populations, it is not uncommon for an individual to inherit a gene for one or other form 
of thalassaemia and a structural haemoglobin variant (Provan and Gribben, 2000, 
Dispenzieri, 2001, Weatherall and Clegg, 2001 b). Haemoglobinopathies are most easily 
understood on the basis of an elementary understanding of haemoglobin structure. 
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2.2.1 Human haemoglobin structure and function 
         Human haemoglobins are tetrameric molecules containing two pairs of globin 
chains, each of which is associated with an iron-containing heme group. The heme 
groups allow the haemoglobin molecules to transport the oxygen to the tissues of the 
body (Clark and Higgins, 2000, Dispenzieri, 2001).  
 
The structure of human haemoglobin (Hb) changes during development. Normal adult 
(HbA) and fetal (HbF) haemoglobins have α-chains that are combined with β- (HbA, α2 
β2), δ- (HbA2, α2 δ2) or γ-chains (HbF, α2 γ2), whereas in the embryo, α-like chains called 
ζ-chains combine with γ- (Hb Portland, ζ2 γ2) or ε-chains (Hb Gower 1, ζ2 ε2), and α- and 
ε-chains form Hb Gower 2 (α2 ε 2 ). Embryonic haemoglobin is confined to the yolk-sac 
stage of development and thereafter is replaced by HbF until shortly before term. After 
birth, HbA and HbA2 replace HbF over the first year of life while in normal adults small 
amounts of HbF, constituting nearly 1% of the total haemoglobin, continue to be 
produced. The α-like genes are encoded on chromosome 16, whereas the β-like genes 
form a cluster on chromosome 11(Clarke and Higgins, 2000, Weatherall, 2001) (Fig. 
2.1). 
 
The main function of haemoglobin is to carry oxygen to the tissues. Other functions 
include the transport of carbon dioxide (CO2) and a buffering action (reduction of the 
changes in PH) in a red cell (Bain, 2001). 
 
 8 
 
Figure 2.1 The α-globin gene cluster on chromosome 16 and the β-globin gene 
cluster on chromosome 11 (Source: Weatherall, 2001). 
 
 
 
2.2.2 Classification of thalassaemia 
          Thalassaemias can be subdivided into two main groups α and β thalassaemia. 
Although each can be further classified into different subgroups, all these disorders have 
one thing in common; there is always imbalanced globin synthesis (Necheles et al., 1969, 
Clarke and Higgins, 2000). The differences are summarized in figure 2.2. 
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                                                               β thalassaemia 
                                α2 γ2                                                             α2 β2                                                                                     
                                                                                  Excess                                                                                               
            
                Selective survival of F-cells                                Precipitate in marrow  
                Increased level in blood                                      Ineffective erythropoiesis  
                                                              
                                                                α thalassaemia 
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    Excess 
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                                                                                            Precipitates in red cells 
                                                                                            Haemolytic anaemia                                                                                    
 
Figure 2.2 A simplified representation of the differences in the haemoglobin 
patterns between α and β thalassaemias. Shaded boxes indicate defective globin 
synthesis (Source: Weatherall & Clegg, 2001 a). 
    
 The disease can be described at several levels. First, there is a clinical (phenotypic) 
classification based on its severity. Second, thalassaemias can be classified according to 
their genetic basis by describing the globin subunits which is synthesized at a reduced 
rate. Finally, it is now possible to subclasssify many thalassaemias according to the 
particular mutation that is responsible for defective globin synthesis (Old, 2003). 
 
A. Clinical classification 
           Based on the severity of the disease, thalassaemia can be classified into major, 
minor and intermedia. Thalassaemia major is severe and transfusion dependant while 
thalassaemia minor is symptomless condition that can be only identified 
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haematologically. It is usually presents the carrier state or trait. Thalassaemia intermedia 
includes a wide spectrum, ranging from disorders which are not as severe as major forms 
to asymptomatic conditions which are only slightly more severe than the trait. In 
addition, some heterozygotes for thalassaemia mutations are clinically and 
haematologically normal; they are sometimes designated ‘silent’ carriers (Weatherall & 
Clegg, 2001 a). 
 
B.  Genetic classification 
           According to genetic classification, thalassaemia can broadly divided into α, β, γ, 
δβ, δ, and εγδβ varieties depending on which globin or globins are under produced. 
 
2.3 Different forms of thalassaemia  
 
2.3.1 Beta (β) Thalassaemias 
           β thalassaemias are characterized by reduced synthesis of the β-globin chain and a 
subsequent imbalance in α/β-globin chain ratio that results in chronic hemolytic anemia 
(Aessopos et al., 2007). The beta thalassaemia include four clinical syndromes of 
different severity: two conditions are generally asymptomatic, the silent carrier state and 
β thalassemia trait which usually results from inheritance of one mutant β-globin gene, 
and two require medical management, thalassaemia intermedia and thalassaemia major 
(Olivieri, 1999). The latest two will be discussed in details in this text due their clinical 
importance and relevance to this study. 
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A. β Thalassaemia Major 
           β thalassaemia major patients are those with homozygosity or compound 
heterozygosity for β thalassaemia who are dependent on blood transfusions to maintain 
life beyond early childhood (Bain, 2001). Thalassaemia major (TM) usually causes 
profound anaemia with the haemoglobin value in the range of 2.0 to 6.5 g/dl which starts 
during the first year of life (Olivieri, 1999, Weatherall, 2001). The Thalassaemia Clinical 
Research Network (TCRN) has defined TM as homozygous or compound heterozygous β 
thalassaemia requiring 8 or more transfusions in one year. By TCRN definition, patients 
with β thalassaemia required fewer than 8 transfusions annually are considered 
thalassaemia intermedia (Cunningham et al., 2004).  
 
Typical  features of under treated thalassaemia major children include impaired growth, 
pallor mucous membrane, brown skin pigmentation, poor musculature, 
hepatosplenomegaly and characteristic skeletal and maxillofacial deformities (Abu 
Alhaija et al., 2002, De Sanctis, 2002, Cunningham et al., 2004, Rund and Rachmilewitz, 
2005). The childhood of these children is interrupted with numerous complications which 
include pathological fractures, recurrent infections and extramedullary haemopoietic 
masses (Wonke, 1998, Cunningham et al., 2004). 
 
On the other hand, well-transfused thalassaemic children often remain asymptomatic 
until the early childhood. Their future course then depends on weather they have received 
adequate iron chelation. If not, they begin to show signs of hepatic, endocrine and cardiac 
complications (Borgna-Pignatti et al., 2004, Borgna-Pignatti et al., 2005, Charafeddine et 
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al., 2008). Children who are adequately transfused and are compliant to chelation therapy 
have better survival and less complications (Borgna-Pignatti et al., 2004, Borgna-Pignatti 
et al., 2005, Charafeddine et al., 2008). However, in some cases they may suffer from the 
side effect of long-term chelation therapy (Cunningham et al., 2004). 
 
B. β Thalassaemia Intermedia  
           β Thalassaemia intermedia (TI) encompasses a wide clinical spectrum. Mildly 
affected patients are completely asymptomatic until adult life, experiencing only mild 
anemia and maintaining hemoglobin levels between 7 and 10 g/dl. These patients require 
only occasional blood transfusions, if any. Patients with more severe thalassemia 
intermedia generally present between the ages of 2 and 6 years, and although they are 
able to survive without regular transfusion therapy, growth and development can be 
retarded (Ho et al., 1998, Taher et al., 2006). In few words, Aessopos et al., (2005) 
described thalassaemia intermedia patients as those who have clinical symptoms present 
after the first year of life with a milder anaemia than thalassaemia major that do not 
require regular transfusions and a longer life expectancy. (Aessopos et al., 2005) 
 
Thalassaemia intermedia is equally very heterogeneous at the genotype level. These 
patients are most commonly homozygotes or compound heterozygotes for β-thalassemia, 
having both β-globin loci affected. Less frequently only a single β-globin locus is 
mutated, the other being completely normal. The mild clinical characteristics of 
thalassaemia intermedia compared to thalassaemia major result from three different 
mechanisms (Galanello and Cao, 1998, Ho et al., 1998): 
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· Inheritance f a mild or silent beta-chain mutation. 
· Co-inheritance of determinants associated with increased γ-chain production. 
· Co-inheritance of α-thalassaemia.  
 
The clinical manifestations of β thalassaemia intermedia are extremely variable. In some 
cases the disorder presents early in life with anaemia, while in others it may not appear 
until later due to a complications such as hypersplenism. Growth and development may 
be normal or may be retarded. The major symptoms in early childhood are anaemia and 
jaundice. There is always some degree of splenomegaly and hepatomegaly (Weatherall 
and Clegg, 2001 a, Taher et al., 2006, El Rassi et al., 2008). The bone changes are 
extremely variable and range from almost none at all to severe skeletal deformity similar 
to that seen in poorly managed TM patients (Mohamed and Jackson, 1998, Mortazavi and 
Khojasteh, 2007) . 
          
2.3.2 Haemoglobin E/β Thalassaemia 
          The interaction of thalassaemias with structural haemoglobin variants are of   
considerable clinical importance. Although the majority of them are rare, some forms 
such as sickle cell β thalassaemia and HbE/ β thalassaemia cause a considerable public 
health problem in some parts of the world. Indeed, because of the particularly high 
frequency of β thalassaemia and HbE in Asia, HbE / β thalassaemia is one of the most 
important varieties of thalassaemia (Weatherall and Clegg, 2001 a). It has replaced β 
thalassaemia as the most common thalassaemia disorder in many regions including 
coastal North America with at least million people affected worldwide most of them in 
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Asia (Lorey, 2000, Vichinsky, 2007). In many Southeast Asian countries, HbE/ β 
thalassaemia is the most common cause of transfusion-dependent thalassaemia (Hurst et 
al., 1983, Weatherall and Clegg, 2001 b).The details of this disorder will be discussed 
next. 
 
Haemoglobin E is a β-chain variant (α2β2 26Glu→Lys) caused by a substitution of glutamic 
acid by lysine at codon 26 of the β-globin gene. The βE chain is synthesized at a reduced 
rate compared with βA. The result of the reduced rate of synthesis of βE chain and 
therefore of haemoglobin E is that heterozygotes, compound heterozygotes and 
homozygotes show some thalassaemic features and thus is considered a thalassaemic 
haemoglobinopathies (Bain, 2001, Vichinsky, 2007). Heterozygous (HbE trait) or 
homozygotes (HbE disease) produces clinically mild condition while the most significant 
clinical consequences occur with the compound heterozygote state of Hb E/β 
thalassaemia, leading to a variable phenotype ranging from thalassaemia minor through 
thalassaemia intermedia to thalassaemia major with haemoglobin levels range from 3 to 
13 g/dl. However, the majority of patients have a disease of moderate severity with 
average haemoglobin of 7.7 g/dl (Weatherall, 2000, Fucharoen et al., 2000, Fucharoen 
and Winichagoon, 2000). 
 
The clinical severity of Hb E/β thalassaemia is very variable. The most severely affected 
individuals are transfusion-dependent and have early onset of symptoms with marked 
anaemia, hepatosplenomegaly, intermittent jaundice, growth retardation and 
overexpansion of the bone marrow cavity leading to facial deformity and malpositioned 
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teeth. Less severely affected individuals may have later onset with mild anaemia, 
splenomegaly and facial deformity but do not require regular transfusions to maintain 
life. Occasional patients are only mildly affected. However, during pregnancy or 
intercurrent infection, patients who are not usually transfusion-dependent may become 
sufficiently anaemic to require transfusion (Fucharoen et al., 2000, Fucharoen and 
Winichagoon, 2000, Premawardhena et al., 2005, Panigrahi et al., 2005).  
 
2.3.3 Alpha (α ) thalassaemias 
           The α thalassaemias are a group of inherited disorders of haemoglobin in which 
the production of α-globin chains is partially or completely suppressed (Bernini and 
Harteveld, 1998). The severity of the defect is very variable. At one extreme is a 
completely asymptomatic condition resulting from deletion or dysfunction of on of the 
four α genes. At the other extreme is haemoglobin Bart's hydrops fetalis, a condition 
generally incompatible with life resulting from deletion of all four α genes and a 
consequent total lack of α-globin synthesis which causes death in utero or shortly after 
birth (Bain, 2001, Chui et al., 2003, Chui, 2005). The clinical phenotypes of α 
thalassaemia reflect the degree of defective α chain synthesis.  
 
Hb H disease is one of the important varieties of α thalassaemia which constitutes a 
serious health problem in Southeast Asia and southern China (Cohen et al., 2004). 
Patients with Hb H disease have only one active α-globin gene, often due to the deletion 
of three other α-globin genes (Chui, 2005). They are sometimes known as ‘deletional’ Hb 
H disease. Approximately 20% of patients with Hb H disease have deletion of two α-
 16 
globin genes plus inactivation of the third α-globin gene by non-deletional mutation such 
as Hb Constant spring (Hb CS), Pakse, or Quong Sze mutations. This group of disorders 
is known as ‘non-deletional’ Hb H disease (Chui, 2005).  Hb CS is the most common 
non-deletional α thalassaemia mutation associated with Hb H disease (Vichinsky, 2005). 
Hb H, Hb H-Constant Spring and homozygous α thalassaemia affect at least a million 
people worldwide (Weatherall and Clegg, 2001 b).  
 
Hb H disease is generally considered to be a clinically mild disorder. However, there is a 
marked phenotypic variability, ranging from asymptomatic, to need for periodic 
transfusions, to severe anaemia with haemolysis and hepatosplenomegaly, and even to 
fatal hydrops fetalis syndrome in utero (Chui et al., 2003). The severity of Hb H disease 
is highly variable. A moderately severe anaemia and hepatosplenomegaly characterize it. 
Typically, the haemoglobin level is maintained at around 9.5 g/dl and chronic transfusion 
support is unnecessary. However, 29 to 50% of deletional Hb H disease patients require 
intermittent transfusion therapy. Extramedullary haemopoiesis is uncommon (Weatherall 
and Clegg, 2001 a, Vichinsky, 2005).  
 
Patients with Hb H-Constant Spring disease usually are more anaemic, more 
symptomatic, more prone to have significant hepatosplenomegaly, and more likely to 
require transfusions with average haemoglobin level of 2 g/dl less than in deletional Hb H 
disease (Mohamed and Jackson, 1998, Chui et al., 2003). It was estimated that 90% of 
patients with Hb H-CS disease have been intermittently transfused, and up to 40% have 
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required repeated transfusions, particularly in early infancy and in later adulthood (Cohen 
et al., 2004).  
      
2.4 Pathophysiology of thalassaemia  
            Systemic manifestations of thalassaemia and their remarkable clinical diversity 
can be easily understood once the pathophysiological mechanism of the disease 
identified. Indeed, the fundamental disease process in both α and β-thalassaemia, which is 
imbalanced globin synthesis, is the same. However, their pathophysiology differs because 
of the different properties of the particular globins that are produced in excess 
(Weatherall and Clegg, 2001 a).  
 
The pathophysiology of β thalassaemia is reasonably well understood, at least in outline 
(Weatherall, 1998). The basic defect is the reduction in β-globin output ranging from a 
minimal deficit (β+) to complete absence (β0). This leads to imbalanced globin chain 
synthesis and to the production of an excess α chains. The free α-globin chains precipitate 
in the red cell precursors causing their premature destruction in the bone marrow; a 
process known as ‘ineffective erythropoiesis. Red cells that survive to reach the 
peripheral blood are prematurely destroyed in the spleen. Anaemia in β thalassaemia thus 
results from a combination of ineffective erythropoiesis, peripheral haemolysis and an 
overall reduction in haemoglobin synthesis (Weatherall, 1998, Thein, 2005). 
 
The anaemia in turn results in increase in the erythropoietin production, which leads to 
intense proliferation and expansion of the bone marrow with the resulting skeletal 
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deformities (Wonke, 1998, Thein, 2004, Thein, 2005). The hyperplasia of bone marrow 
leads to increased iron absorption and iron loading, often exacerbated by the need of 
regular blood transfusion, which lead to iron deposition in tissues, organ failure and 
finally death if excess iron is not removed (Weatherall and Clegg, 2001 a, Thein, 2004, 
Borgna-Pignatti et al., 2005). Generally, factors which reduce the degree of chain 
imbalance and the magnitude of α chain excess in red cell precursors, have an 
ameliorating effect on the β thalassemia phenotype (Thein, 2004). Figure 2.3 summarize 
the pathophysiology of β thalassemia. 
 
On the other hand, the fundamental defect in α thalassaemia is like β thalassaemia, 
imbalanced globin synthesis. However, there are two major pathophysiological 
differences. First, the α thalassaemias, unlike β thalassaemias, are manifest in fetal life 
because α chains are shared by both fetal and adult haemoglobin (Fig. 2.2). Second, the 
properties of the excess γ and β chains that are synthesized in α thalassaemia are quite 
different from the excess α chains that are produced in β thalassaemia (Weatherall and 
Clegg, 2001 a). Unlike excess α chains in β thalassaemia, they do not precipitate in red 
cell precursors, but they form the soluble homotetramers, haemoglobin Bart's (γ4) and Hb 
H (β4). These homotetramers often become attached to the cell membranes of circulation 
erythrocytes causing local oxidative damage, membrane dysfunction and shortened red 
cell survival (Weatherall, 1998, Chui et al., 2003). It appears that the ability to produce 
these soluble tetramers allows some effective erythropoiesis to occur and hence 
haemolysis is the major cause of anaemia in α thalassaemia, although ineffective 
erythropoiesis plays a pathogenic role. In contrast, ineffective erythropoiesis is the 
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dominant cause of the anaemia in β thalassaemia major and intermedia (Weatherall, 
1998, Weatherall and Clegg, 2001 a, Schrier, 2002, Chui et al., 2003). 
 
 
 
 
Figure 2.3 A summary of the main pathophysiological features of β thalassaemia 
(Source: Weatherall, 1998). 
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Indeed, the interactions of thalassaemias with the structural haemoglobin variants result 
in a variety of diseases with much more complex pathophysiological mechanisms. As an 
example, the extraordinary clinical variation in Hb E/β thalassaemia is still one of the 
unsolved pathophysiological issues in human thalassaemia (Schrier, 2002, Vichinsky, 
2007). The instability of Hb E plays a minor role in its pathophysiology while the 
interaction between Hb E and β thalassaemia alleles is the main determinant. The globin 
chain imbalance that results from these mutations correlates with the severity of the 
disease (Fucharoen and Winichagoon, 2000, Vichinsky, 2007). However, this does not 
explain the whole problem because some patients with the same mutations within a 
family may show significant clinical severity. The variability is probably due to weather 
the patient is heterozygotes for β0 thalassaemia or β+ thalassaemia mutations (Vichinsky, 
2007). Co-inheritance of α thalassaemia mutations may also modulate severity (Cohen et 
al., 2004).  
 
It has been stated that oxidant injury could be the cause of haemolysis and that 
accelerated apoptosis is responsible for ineffective erythropoiesis (Schrier, 2002). 
Pootrakul et al., (2000) study has found that Hb H disease have minimal ineffective 
erythropoiesis and apoptosis comparing to Hb CS which have a distinct increase in 
ineffective erythropoiesis and apoptosis. This study has also found that patients with Hb 
E/β thalassaemia had the most ineffective erythropoiesis and the most erythroid apoptosis 
among the three groups. (Pootrakul et al., 2000)  
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In summary, it is now clear that the cardinal feature of all thalassaemias is imbalanced 
globin synthesis. Thus, any factor that lessens the degree of imbalance will have a 
beneficial effect on the clinical phenotype (Thein, 2004). 
 
2.5 Complications of thalassaemia 
          Complications of thalassaemia can be arranged under three main headings 
according to etiology. Indeed, many of the complications are multifactorial with complex 
etiology and cannot be easily categorized under a specific cause. Only complications 
related to this study are discussed.  
 
2.5.1 Ineffective erythropoiesis and anaemia related complications 
 
2.5.1.1 Erythroid hyperplasia 
           Erythroid hyperplasia is a common complication in un-transfused or 
undertransfused thalassaemia patients. It is a compensatory mechanism for ineffective 
erythropoiesis and haemolysis that leads to expansion of the haemopoietic bone marrow 
and extramedullary erythropoiesis with their subsequent complications (Drew and Sachs, 
1997, Mohamed and Jackson, 1998, Weatherall and Clegg, 2001 a). Main problems due 
to erythroid hyperplasia are: 
 
 A. Craniofacial and skeletal deformity   
           The characteristic deformities of the skull and face and other skeletal features of 
severe thalassaemia were emphasized in many early and late descriptions of the disease             
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(Poyton and Davey, 1968a, Jackson et al., 1987, Cannell, 1988, Bassimitci et al., 1996, 
Abu Alhaija et al., 2002, Amini et al., 2007). These deformities are unusual before six 
months of age and are most commonly seen in children over one year old with the 
homozygotes develop more pronounced skeletal abnormalities and earlier symptoms than 
heterozygotes (Tyler et al., 2006).  
 
In untreated or under treated patients, the resulting anaemia causes expansion of the bone 
marrow up to 15-30 times normal and affects every part of the skeleton (Wonke, 1998, 
Tyler et al., 2006). The most prominent and well-known orofacial features of β 
thalassaemia are prominent cheekbones and a protrusive premaxilla with distinct 
depression of the bridge of the nose, often referred to as ‘rodent’ or ‘chipmunk’ faces 
(Cannell, 1988, Bassimitci et al., 1996, Abu Alhaija et al., 2002). 
 
 Indeed, chipmunk face (Fig. 2.4 B) usually refers to the severest distinguishable form of 
thalassaemia mainly involves maxillary area that shows overgrowth in all directions with 
resultant overbite and protrusion of the exposed anterior teeth (Jackson et al., 1987, Abu 
Alhaija et al., 2002). Whereas, in some patients, a milder deformity described as 
‘mongoloid face’ (Fig.2.4 A) and characterized by prominent frontal and parietal bones, 
sunken nasal bridge, retruding zygomas and upward slants of eyes (Jackson et al., 1987, 
Abu Alhaija et al., 2002). 
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Figure 2.4 Facial appearances in severe β thalassaemia. A. Mongoloid face.  
B. Chipmunk face (Source: Weatherall and Clegg, 2001 a)  
 
These skeletal changes are mirrored by characteristic radiological changes of the skull, 
long bones, ribs and hands. Cephalometric radiographs shows dilatation of the diploic 
space, with subperiosteal bone grows in a series of radiating striations, giving a typical 
‘hair on end’ appearance (Fig.2.5). Marrow overgrowth in frontal, temporal and facial 
bones consistently impedes pneumatization of paranasal sinuses while in the maxillary 
bone it may causes lateral displacement of the orbits and ventral displacement of the 
central incisors (Tunaci et al., 1999, Weatherall and Clegg, 2001 a, Tyler et al., 2006). 
Panoramic and intraoral radiography may show a generalized loss of bone density similar 
to that seen in osteomalacia or osteoporosis, and a thin cortex of the mandible. The 
trabeculae of jaws appear coarse in pattern with enlarged marrow spaces described as 
‘Chicken-wire’ (Poyton and Davey, 1968b, Hes et al., 1990). 
B A 
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Figure 2.5 X-ray showing typical hair on end appearance in severe β thalassaemia 
(Source: Weatherall & Clegg 2001 a). 
 
The radiographic picture of other parts of the skeleton include bulbous expansion of 
posterior and anterior segments of the rib, rib within rib pattern, spine deformities and 
vertebral collapse. Long bones show loss of normal concave outline together with cortical 
thinning and porous rarefaction. Similar changes are seen in the small bones of the hands 
and feet (Tunaci et al., 1999, Weatherall and Clegg, 2001 a, Tyler et al., 2006). Children 
who are not transfused until late childhood or adolescence commonly show premature 
fusion of the growth plates in the tubular bones of extremities (Tunaci et al., 1999). 
Pathological fractures are also a major feature of inadequately transfused patients 
(Basanagoudar et al., 2001). 
 
